null.
Research / Reference
Reference article

Retatrutide (LY3437943): how a triple-receptor agonist works

Null Bio Lab Research Desk · Published October 4, 2026 · Research use only

Scope. This article summarises published pharmacology for readers working with retatrutide as a laboratory reagent. It does not give dosing, administration or usage guidance, and nothing here is a statement about any use in humans. Retatrutide is an investigational compound and, at the time of writing, is not an approved medicine.

What retatrutide is

Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly and Company. It is a single molecule that acts as an agonist at three related G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).1

That design makes it a “unimolecular” triple agonist, as opposed to a combination of separate molecules. It extends the earlier approach of dual GIP/GLP-1 agonism, which the developers cite as the background for adding glucagon-receptor activity.2

The three receptors

  • GLP-1R. The receptor for glucagon-like peptide-1, an incretin hormone. In the literature, GLP-1 receptor agonism is associated with reduced food intake, slower gastric emptying and glucose-dependent insulin secretion.2
  • GIPR. The receptor for glucose-dependent insulinotropic polypeptide, the second major incretin. GIP signalling is also involved in insulin secretion and lipid handling.2
  • GCGR. The receptor for glucagon. Unlike the two incretin receptors, glucagon signalling is linked to hepatic metabolism and, in preclinical work, to increased energy expenditure.1

In the original in vitro characterisation, the molecule showed balanced activity at GCGR and GLP-1R, with comparatively stronger activity at GIPR.1 That receptor activity profile is the defining pharmacological feature reported for the compound.

Why combine them in one molecule

The preclinical rationale reported by the developers is that the three activities act on different parts of energy balance. In obese mouse models, the effect on body weight was reported to be augmented when GCGR-mediated increases in energy expenditure were added to the reduction in calorie intake driven by GIPR and GLP-1R activity.1

Glucagon-receptor agonism on its own has not been a practical single target, because of its effects on glucose. The reasoning behind a triple agonist is that combining it with GLP-1 and GIP activity may allow the energy-expenditure component to be explored alongside the incretin effects.2 This is a hypothesis from the primary literature, and it is the subject of continuing study rather than a settled conclusion.

Human data on the compound come from trials run by its developer. Early-phase safety, tolerability and pharmacokinetic findings were published in 2022, including a multiple-ascending-dose study in people with type 2 diabetes.2 This article does not summarise clinical outcomes, because it is written for laboratory readers and is not a source of information on any use in people.

Development and regulatory status

Retatrutide has been described as investigational throughout the published literature. As of October 2026 it has not been approved by the U.S. FDA or the European Medicines Agency, and it remains in late-stage development. Regulatory timelines change frequently, so readers should consult the developer's announcements and the relevant regulatory agency for current status rather than relying on this page.

Because it is unapproved, material sold under this name is not a licensed medicine anywhere. Null Bio Lab supplies it solely as a reagent for in-vitro laboratory research, as set out in our terms.

Verifying research material: reading a COA

For a peptide of this size and complexity, a certificate of analysis (COA) is the main way to check that a batch is what it claims to be. A useful COA from an independent laboratory should show:

  • Purity by HPLC. The chromatogram peak area for the main compound as a percentage of total peaks. Look at the chromatogram itself, not only the summary figure.
  • Identity by mass spectrometry. The measured molecular mass should match the expected mass for the compound. Purity alone does not prove the right molecule is present.
  • Quantity. The measured peptide content per vial, which can differ from the labelled amount.
  • Batch traceability. The batch or lot number on the report should match the number on the vial and packaging.
  • Independent verification. A third-party laboratory, ideally with a verification key or link you can check on the lab's own website instead of trusting a PDF alone.

Null Bio Lab publishes independent test reports for tested batches on the COA page, including the report for the current NB-3AG batch.

References

  1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340.
  2. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5. PMID 36354040.

For newly published papers on this and other peptides, see the live feed on the Research Desk.